Table 3. Outcomes Comparing Dual Immune Checkpoint Inhibitor With Single-Agent Anti-PD1 in the Neoadjuvant Setting.
| Variable | No. (%) | OR (95% CI) | P value | |
|---|---|---|---|---|
| DCPI | Anti-PD1 | |||
| Total patients | 206 | 182 | NA | NA |
| Radiologic response evaluated | 204 | 160 | NA | NA |
| rCR | 21 (10.3) | 9 (5.6) | 1.93 (0.86-4.33) | .11 |
| rOOR | 102 (50.0) | 73 (45.6) | 1.19 (0.79-1.81) | .41 |
| rPD | 24 (11.8) | 25 (15.6) | 0.72 (0.39-1.32) | .29 |
| Pathologic response evaluated | 205 | 173 | NA | NA |
| pCR | 93 (45.4) | 36 (22.5) | 3.16 (1.99-4.99) | .001 |
| Adverse events | ||||
| Grade 3 or 4 irAE | 70 (33.9) | 22 (12.1) | 3.75 (2.20-6.37) | .001 |
| Unable to complete NAT | 95 (46.1) | 14 (7.7) | 10.27 (5.58-18.91) | .001 |
| Planned surgical resection | 194 (94.2) | 166 (91.2) | 1.56 (0.72-3.39) | .26 |
Abbreviations: DCPI, dual checkpoint inhibition; irAE, immune-related adverse event; NA, not applicable; NAT, neoadjuvant immunotherapy; OR, odds ratio; pCR, pathologic complete response; PD1, programmed cell death protein-1; rCR, radiologic complete response; rOOR, radiologic overall objective response; rPD, radiologic progressive disease.